加速期及急变期MPN中强化与非强化减原始细胞策略的结局
该回顾性分析纳入138例BCR::ABL1阴性MPN加速期/急变期患者,强化组81例、非强化组57例。强化组总体最佳缓解率77%(62/81),非强化组39%(21/54);TP53突变和RAS通路突变与强化治疗反应差相关,体能状态差与两组治疗反应差均相关。
要点
- 强化减原始细胞策略总体最佳缓解率77%(62/81),非强化组39%(21/54)。
- daunorubicin+ara-C与FLAG-IDA/NOVE-HiDAC总体最佳缓解率相似(74% vs 78%,P=.78)。
- TP53突变(OR 8.2)和RAS通路突变(OR 5.1)与强化治疗反应差相关。
核心结论
- 强化减原始细胞策略在MPN-AP/BP中总体最佳缓解率高于非强化策略,但多数缓解为恢复至慢性期MPN。
- TP53突变、RAS通路突变和较差体能状态与治疗反应差相关。
- 无论减原始细胞治疗反应如何,配对样本中均存在显著残留突变负荷。
研究设计与样本
- 回顾性分析纳入138例BCR::ABL1阴性MPN加速期/急变期患者,强化组81例,非强化组57例。
- 采用Princess Margaret癌症中心制定的临床相关缓解标准。
- 非强化方案为基于低甲基化药物的方案,强化方案为AML型强化方案。
主要发现
- 强化组总体最佳缓解(CR+CRi+恢复至cMPN)77%(62/81),非强化组39%(21/54)。
- daunorubicin+ara-C组总体最佳缓解74%(23/31),FLAG-IDA/NOVE-HiDAC组78%(39/50),P=.78。
- daunorubicin+ara-C组需要第二次诱导者29%(9/31),FLAG-IDA/NOVE-HiDAC组4%(2/50),P=.002。
- 全队列缓解者中恢复至cMPN占66%(55/83),CR占30%(25/83),CRi占4%(3/83)。
关键数值与推荐
- TP53突变与强化治疗反应差相关:OR 8.2(95%CI 2.01, 37.1),P=.004。
- RAS通路突变与强化治疗反应差相关:OR 5.1(95%CI 1.2, 23.7),P=.03。
- 体能状态差(ECOG)与强化治疗反应差相关:OR 10.4(95%CI 2.0, 78.5),P=.009。
- 体能状态差(ECOG)与非强化治疗反应差相关:OR 12(95%CI 2.04, 230.3),P=.02。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Transformation of BCR::ABL1-negative myeloproliferative neoplasms (MPN) to an accelerated or blast phase is associated with poor outcomes. The efficacy of acute myeloid leukemia (AML)-type intensive and nonintensive hypomethylating agent-based regimens is not well studied. We therefore performed a retrospective analysis of patients with MPN-AP/BP (N = 138) treated with intensive (N = 81) and nonintensive (N = 57) blast-reduction strategies. We used clinically relatable response criteria developed at the Princess Margaret Cancer Centre. The overall best response, comprising complete remission (CR), complete remission with incomplete hematologic recovery (CRi), and reversion to chronic phase MPN (cMPN), in the intensive and nonintensive groups was 77% (62 of 81) and 39% (21 of 54), respectively. Similar overall best response rates were observed in patients receiving induction with daunorubicin combined with cytarabine arabinoside (daunorubicin + ara-C) (74% [23 of 31]) or FLAG-IDA/NOVE-HiDAC (78% [39 of 50], P = .78). However, patients receiving daunorubicin + ara-C more often required second inductions (29% [9 of 31] vs 4% [2 of 50], P = .002). Most responses in the entire cohort were reversions to cMPN (55 of 83 [66%]). CR and CRi comprised 30% (25 of 83) and 4% (3 of 83) of responses, respectively. Mutations in TP53 (overall response [OR] 8.2 [95% confidence interval [CI] 2.01, 37.1], P = .004) and RAS pathway (OR 5.1 [95%CI 1.2, 23.7], P = .03) were associated with inferior treatment response for intensively treated patients, and poorer performance status (Eastern Cooperative Oncology Group) was associated with inferior treatment response in both intensively (OR 10.4 [95% CI 2.0, 78.5], P = .009) and nonintensively treated groups (OR 12 [95% CI 2.04, 230.3], P = .02). In patients with paired samples before and after therapy (N = 26), there was a significant residual mutation burden remaining irrespective of response to blast-reduction therapy.
引用
- Davidson MB, Kennedy JA, Capo-Chichi JM, et al. Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN. Blood Adv. 2024. PMID: 38170760. doi:10.1182/bloodadvances.2023011735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。